| NCT07020221 | A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2025-06-24 | 2028-09 | 2028-09 |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | RECRUITING | PHASE2 | 2024-10-30 | 2027-10 | 2025-12 |
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | RECRUITING | PHASE3 | 2024-03-18 | 2031-02-09 | 2028-10-15 |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-03-22 | 2027-08-31 | 2026-08-31 |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-08-01 | 2026-01-01 | 2025-12-24 |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | RECRUITING | PHASE1, PHASE2 | 2022-04-12 | 2027-04 | 2025-09 |
| NCT05187169 | Food Effect of VS-6766 in Healthy Adult Subjects | COMPLETED | PHASE1 | 2021-12-16 | 2022-04-12 | 2022-04-12 |
| NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | COMPLETED | PHASE2 | 2020-12-31 | 2023-12-12 | 2023-08-29 |
| NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | ACTIVE_NOT_RECRUITING | PHASE2 | 2020-12-21 | 2026-12 | 2024-11-15 |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | TERMINATED | PHASE1 | 2016-10 | 2018-12-28 | 2018-08-28 |
| NCT02651727 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects | TERMINATED | PHASE1 | 2015-09 | 2017-01 | 2017-01 |
| NCT02913716 | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects | COMPLETED | PHASE1 | 2015-08 | 2015-09 | 2015-09 |
| NCT02372227 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma | TERMINATED | PHASE1 | 2015-01 | 2015-10 | 2015-10 |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | TERMINATED | PHASE2 | 2013-12-12 | 2019-06-19 | 2019-06-19 |
| NCT01991938 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | TERMINATED | PHASE1 | 2013-11 | 2016-12 | 2016-12 |
| NCT01943292 | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | COMPLETED | PHASE1 | 2013-09-02 | 2014-06-09 | 2014-06-09 |
| NCT01951690 | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | COMPLETED | PHASE2 | 2013-09 | 2016-06 | 2016-06 |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma | TERMINATED | PHASE2 | 2013-09 | 2016-01 | 2016-01 |
| NCT01849744 | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies | TERMINATED | PHASE1 | 2013-06 | 2017-06 | 2017-04 |
| NCT01778803 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer | COMPLETED | PHASE1 | 2013-02-26 | 2015-02-23 | 2015-02-23 |
| NCT00787033 | A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies | COMPLETED | PHASE1 | 2008-12 | 2012-02 | 2011-03 |
| NCT00666926 | Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms | COMPLETED | PHASE1 | 2005-12 | 2009-04 | 2009-04 |
| NCT02215629 | Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | WITHDRAWN | PHASE1 | | 2016-11 | 2016-09 |